27 June 2022 – On June 21, 2022, +ND Capital announced the acquisition of Dutch cell therapy company CellPoint by Belgian biotech company Galapagos NV (Euronext &NASDAQ: GLPG).

As sole venture investor in CellPoint, a company dedicated to developing CAR-T therapies at the point-of-care, the sale underlines +ND Capital's success in Europe, being its second exit after Arctos Medical sale to Novartis.

Walder Wyss has advised +ND Capital through its entire investment and in the sale transaction. The Walder Wyss team was led by Luc Defferrard (Partner, Corporate/M&A) and included Michael Kündig (Senior Associate, Corporate/M&A) and Alice Vorburger (Associate, Corporate/M&A).